Alexander Gintsburg, scientific director of the Gamaleya National Research Center for Epidemiology and Microbiology, announced the emergence of preliminary indicators suggesting an immune response in the first patient to undergo testing of the Russian vaccine against melanoma skin cancer.
Gintsburg explained that laboratory tests showed initial changes linked to the production of “cytokines,” which are indicators used to assess the immune system’s reaction to the treatment, noting that the full immunological results are still under follow-up and study.
Last April, Russia began the first clinical use of the “Neooncovac” vaccine, developed using messenger RNA (mRNA) technology and intended to combat cancerous tumors, in a research trial considered one of the unprecedented scientific steps in the field of melanoma skin cancer treatment.
